Praxis Precision Medicines

PRAX · NASDAQ

$264.49+$4.32 (+1.66%)TodayMarket closed · Oct 20, 7:31 PM ET

Prev close $260.17

PRAX analyst rating

BuyConsensus of 19 analysts over the last 12 months. 89% rate it a buy.

Strong buy0
Buy17
Hold1
Underperform1
Sell0

12-month price target · 21 analysts

Average $641.79 (+142.7% upside)

Low: $189.88
Now: $264.49
High: $1,261.05

Upgrades and downgrades

The latest rating actions, newest first

PRAX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 16, 2026	Initiates	Overweight	$700.00	44%
UBS	Oct 15, 2026	Initiates	Buy	$706.00	—
HC Wainwright & Co.	Oct 15, 2026	Maintains	Buy	$1,201.00	50%
HC Wainwright & Co.	Oct 6, 2026	Maintains	Buy	$1,201.00	50%
BTIG	Oct 6, 2026	Maintains	Buy	$810.00 → $826.00	20%
HC Wainwright & Co.	Sep 24, 2026	Maintains	Buy	$1,201.00	50%
Needham	Sep 24, 2026	Maintains	Buy	$582.00	47%
Goldman Sachs	Aug 21, 2026	Maintains	Buy	$470.00 → $575.00	0%
RBC Capital	Aug 7, 2026	Maintains	Outperform	$449.00 → $462.00	49%
Wells Fargo	Aug 7, 2026	Maintains	Equal-Weight	$323.00 → $362.00	29%

The case for and against

Updated Oct 14, 2026

Bull case

Praxis Precision Medicine is supported by a diversified late-stage pipeline that gives it multiple shots at meaningful clinical and commercial value, including ulixacaltamide in essential tremor, relutrigine in DEEs, and additional programs across movement disorders and epilepsy. The ulixacaltamide data are especially encouraging, with Study 1 in 473 patients showing mADL11 improvement of 4.3 points versus 1.7 on placebo at Day 56 and Study 2 showing 55% of stable responders maintained response versus 33% on placebo, reinforcing both efficacy and durability. Relutrigine further strengthens the thesis, with 46% and 53% placebo-adjusted seizure reduction in EMBOLD, a December 27, 2026 PDUFA for SCN2A and SCN8A DEEs, and EMERALD topline data expected in 4Q26 that could materially broaden its addressable market.

Bear case

Praxis Precision Medicine is viewed negatively because its thesis still hinges on clinical-stage assets with no approved products, leaving valuation exposed to binary trial outcomes, regulatory uncertainty, and execution risk. Competition is also intensifying in ET, epilepsy, and DEE, with other therapies already ahead in development, while dependence on third-party suppliers adds another layer of delay risk. Even where early signals exist, expectations for only a 20-30% placebo-adjusted reduction and possible deterioration in larger studies suggest limited efficacy durability, weakening the fundamental case.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.